Effect of Crosstalk Between Th17 and Th9 Cells on the Activation of Dermal Vascular Smooth Muscle Cells in Systemic Sclerosis and Regulation of Tanshinone IIA

mengguo liu (✉ liumengguo@126.com)

Huashan Hospital Fudan University

ming li

Zhongshan Hospital Fudan University

wenwen fu

Huashan Hospital Fudan University

Research

Keywords: systemic sclerosis, Th17, Th9, angiopathy, dermal vascular smooth muscle cells, tanshinone IIA

Posted Date: August 6th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-52914/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background: To evaluate the effect of T helper 17 (Th17) cells and Th9 cells on the activation of dermal vascular smooth muscle cells (DVSMCs) in systemic sclerosis (SSc) and regulation of tanshinone IIA.

Methods: The expression of interleukin 17 receptor (IL-17R) and interleukin 9 receptor (IL-9R) in the skin of SSc patients was assessed by immunofluorescence. The expression of *IL-9* and *IL-9R* mRNA in peripheral blood mononuclear cells (PBMCs) of SSc patients were detected by quantitative real-time polymerase chain reaction (qRT-PCR). The [proportion](#) of Th9 cells in PBMCs of SSc patients was sorted by flow cytometry. The effect of IL-9 on the differentiation of Th17 and IL-17 on that of Th9 was detected by flow cytometry. The [proportion](#) of Th9 and Th17 cells in SSc patients was detected by flow cytometry. The level of collagen I, III, α -SMA, IL-9R, IL-17R, JNK, P38, and ERK were analyzed using Western blot (WB).

Results: Th9 cells were highly expressed in SSc. IL-9 stimulated the differentiation of immature T cells into Th17 cells. IL-17 induced the differentiation of immature T cells into Th9 cells. Tanshinone IIA inhibited the differentiation of immature T lymphocytes into Th17 and Th9. WB showed that the combined action of IL-17 and IL-9 upregulated the inflammation and proliferation of DVSMCs. Anti-IL17, anti-IL9, and tanshinone IIA inhibited the functional activation of DVSMCs.

Conclusions: The current results suggested that Th17 and Th9 cells induced the activation of DVSMCs in SSc through crosstalk in vitro, and tanshinone IIA inhibited the process.

Background

Systemic sclerosis (SSc) is an autoimmune disease [1, 2]. Autoimmune abnormality, vasculopathy, and fibroproliferative alterations are three hallmark pathological processes in SSc that are responsible for the most severe clinical manifestations of the disease. These modifications also determine the clinical outcome of the disease and mortality [3]. Vasculopathy and [fibrosis](#) occur in the early stages and exist throughout the course of the disease and are regulated by autoimmunity. Vasculopathy is characterized by vascular endothelial cell inflammation and smooth muscle cell proliferation, which eventually leads to vascular fibrosis and stenosis [4-6]. However, the pathogenesis of SSc-related vasculopathy is not yet understood.

Recent studies have shown an increase in Th17 cells and IL-17 in the skin and peripheral blood of SSc patients [7]. IL-17A induces inflammation of vascular endothelial cells [8]. We also observed that the proliferation and migration of dermal vascular smooth muscle cells (DVSMCs) from media to intima induced by Th17 cells as well as the phenotype transformation from contraction type to synthetic type, which results in over-production of collagen, may play a key role in the pathogenesis of SSc [9-11]. However, whether Th17 cells and other lymphocytes act synergistically in inducing the function of DVSMCs is yet to be elucidated. Recently, IL-9 and IL-9-producing CD4⁺ T cells (Th9 cells) have been found in SSc, suggesting that IL-9 axis might be involved in SSc pathogenesis [12, 13]. Other studies have

shown that IL-9 induces the differentiation of Th17 cells [14, 15]. Nevertheless, none of the studies have specifically addressed whether Th17 and Th9 cells interact among each other to promote the functional activation of DVSMCs in the pathogenesis of SSc.

Thus, the present study elaborated on the effect of Th17 and Th9 cells on SSc patient-derived DVSMCs. We also studied the regulatory effect of tanshinone IIA on this process. Interestingly, we observed that Th17 and Th9 cells might induce the activation of DVSMCs in vitro in SSc through “dialogue,” and tanshinone IIA alleviates this effect.

Methods

SSc patients and healthy controls

A total of 10 patients with SSc (4 men and 6 women) were included in this study after they provided informed consent. All patients were diagnosed according to the 2013 classification criteria for SSc and presented different degrees of clinical manifestations of microangiopathy (for example, Raynaud phenomenon, digital ulcers, telangiectasia, pulmonary hypertension, and renal crisis). In addition, 10 age- and sex-matched healthy individuals (5 men and 5 women), who underwent surgery for non-cutaneous disease evaluation, were enrolled in this study. Blood samples were withdrawn from SSc patients and healthy individuals. The skin tissues of SSc patients were obtained to isolate DVSMCs.

Isolation of SSc patient-derived DVSMCs

The skin tissues of the lesions were disinfected using 75% alcohol and excised surgically under sterile conditions, followed by 6–8 washes in sterile phosphate-buffered saline (PBS) and then soaked in 75% alcohol for 5–10 min. Subsequently, the tissues were washed with PBS containing two types of antibiotics (penicillin and streptomycin). The dermal vascular tissue was isolated under a dissecting microscope, minced, and trypsinized. The undigested tissue was removed using a 200-mesh filter and centrifugation for 10 min at 1500 rpm. Finally, the cells obtained were resuspended and added to the smooth muscle cell basal medium.

Tissue immunofluorescence

The skin tissue of SSc patients was trimmed, dehydrated, embedded, sliced, baked, dewaxed and rehydrated. Skin tissue slices were blocked with 1% bovine serum albumin (BSA) for 30 min and incubated with primary antibody overnight at 4 °C. After incubation with the secondary antibody at room temperature for 1 h, the cell nuclei were stained with 49,6-diamidino-2-phenylindole (DAPI) was used to stain the cell nuclei. The images were scanned using a fluorescence microscope (Olympus, Tokyo, Japan).

Cell immunofluorescence

DVSMCs were plated in 24-well plates with coverslips. At 90–100% confluency, the cells were stimulated for 24 h, followed by fixation with 4% paraformaldehyde for 15 min and permeabilization with 0.5% Triton X-100 for 15 min. Then, the cells were blocked with 1% BSA for 30 min and incubated with primary antibody overnight at 4 °C. After incubation with a secondary antibody at room temperature for 1 h, DAPI was used to stain the cell nuclei. The images were scanned using a fluorescence microscope.

Enzyme-linked immunosorbent assay (ELISA)

The concentration of IL-9 was detected using the ELISA kit (MultiSciences, Hangzhou, China) according to the manufacturer's instructions. An equivalent of 100 µL standard protein samples and cell culture supernatants were added and incubated for 2 h at room temperature. After washing 4–6 times, each well was incubated for 1 h with 50 µL primary IL-9 antibody and then with 100 µL of enzyme-labeled antibody for 1 h at room temperature. After the termination of the reaction, the OD was measured at 450 nm maximum absorption and 630 nm wavelength. The calibrated OD value was obtained by subtracting the 630-nm value from that of 450 nm. The IL-9 concentration data were presented as mean ± SD values.

Real-time RT-PCR

Total RNA of DVSMCs was extracted using TRIzol reagent. Complementary DNA (cDNA) samples were synthesized using the First Strand cDNA Synthesis Kit (Yeasen, Shanghai, China) and oligo (dT) primers. The levels of mRNA of the target genes were examined using SYBR Green PCR Master Mix. The following primer pairs were used:

IL-9

Forward: TCA AGATGCTTCTGGCCATG

Reverse: AGGGAATGCCCAAACAGAGA

IL-9R

Forward: CCAGCACAGGGATCACATTG

Reverse: GCCTGTATAACGCTCCTCCT

β-actin

Forward: AACCATGAGGGAAATCGTGC

Reverse: CAGGATGGCACGAGGAACAT

The $2^{-\Delta\Delta C_t}$ method was used to normalize the transcription to the level of β-actin and to calculate the fold-induction relative to the controls.

Peripheral blood mononuclear cells (PBMCs) and CD4⁺ T cells sorting and flow cytometry detection

PBMCs were obtained by density gradient centrifugation using Ficoll-Hypaque and were cultured in RPMI 1640 medium supplemented with 10% FCS and antibiotics from SSc patients and healthy controls. CD4⁺ T cell subset was sorted using magnetic-activated cell sorting (MACS). The induced cells were incubated with FITC-labeled anti-human CD4 antibody at 4 °C for 30 min. In order to further analyze the production of IL-9 or IL-17, the cells were permeated with permeable buffer and stained with PE-conjugated anti-human IL-9 or anti-human IL-17 at room temperature for 30 min. At the end of the staining, all stained cells were analyzed by flow cytometry.

Western blot

The proteins of DVSMCs were extracted using RIPA lysis buffer (Beyotime, Shanghai, China) supplemented with the protease inhibitor phenylmethanesulfonylfluoride (PMSF). The proteins were separated by 8% SDS-PAGE and transferred onto PVDF membranes. Subsequently, the membranes were blocked with 5% milk for 2 h at room temperature, probed with primary antibodies, including collagen I (1:2000, Abcam), collagen III (1:5000, Abcam), α -SMA (1:1000, CST), p38 (1:1000, CST), phospho-p38 (1:1000, CST), ERK (1:2000, CST), phospho-ERK (1:1000, CST), and GAPDH (1:5000, Proteintech) overnight at 4 °C, and then incubated with appropriate horseradish peroxidase (HRP)-conjugated secondary antibodies for 1.5 h at room temperature. The proteins were detected using ECL detection reagents.

Statistical analysis

The data were statistically analyzed using the SPSS version 20.0 software (SPSS Inc., Chicago, IL, USA). Quantitative data are expressed as the means $\pm$ standard deviation (SD). Data between the patients and healthy individual groups were analyzed using Student's t-test. Data among multiple groups were analyzed using one-way analysis of variance (ANOVA) combined with Bonferroni correction. P-value <0.05 was statistically significant.

Results

1. Correlation between Th9 and SSc

Compared to normal subjects, IL-9R and IL-17R were highly expressed in the skin lesions of SSc patients (**Fig. 1**). *IL-9* and *IL-9R* mRNA levels of PBMCs and IL-9 levels in SSc serum were increased (**Fig. 2**). Flow cytometry showed that the proportion of CD4⁺ IL-9⁺ T cells in PBMCs of SSc patients was significantly higher (**Fig. 3**). The proportion of Th9 was associated with SSc.

2. Crosstalk between Th17 and Th9 cells in vitro and regulation of tanshinone IIA

2.1 IL-9 and SSc serum promote Th17 differentiation and the reversal effect of tanshinone IIA

The results showed that the proportion of Th17 cells in IL-9 and SSc serum groups was significantly higher than that in the control group; however, the proportion of Th17 cells in the IL-9 neutralizing

antibody group was significantly lower than that in the control group, and IL-9 neutralizing antibody decreased the promoting effect of serum on Th17 cells (**Fig. 4A**). These findings indicated that IL-9 stimulates the differentiation of immature T lymphocytes into Th17 cells in vitro, as well as the differentiation of immature T lymphocytes into Th17 cells. The data showed that tanshinone IIA decreases the proportion of Th17 and **inhibits** the effect of SSc serum on Th17 cells as compared to the control (**Fig. 4B**). **Moreover**, the content of IL-17 in the culture supernatant of each group was detected by ELISA. These results showed that IL-9 and SSc serum significantly promotes the secretion of IL-17 by immature T lymphocytes, while IL-9 neutralizing antibody and tanshinone IIA significantly inhibits the secretion of IL-17 by immature T lymphocytes and reverses the triggering effect of IL-9 and SSc serum (**Fig. 4C**).

2.2 IL-17 and SSc serum promote Th9 differentiation and the reversal effect of tanshinone IIA

The results showed that the proportion of Th9 cells in the IL-17 and SSc serum groups was significantly higher than that in the control group; however, the proportion of Th9 cells in IL-17 neutralizing antibody group was significantly lower than that in the control group and IL-17 neutralizing antibody decreased the promoting effect of serum on Th9 cells (**Fig. 5A**). These findings indicated that IL-17 stimulates the differentiation of immature T lymphocytes into Th9 cells in vitro, and IL-17 in the serum of SSc patients stimulates the differentiation of immature T lymphocytes into Th9 cells. In addition, tanshinone IIA decreases the proportion of Th9 and **inhibits** the promoting effect of SSc serum on Th9 cells as compared to the control (**Fig. 5B**). **Moreover**, the content of IL-9 in the culture supernatant of each group was detected by ELISA. The results showed that IL-17 and SSc serum significantly promoted the secretion of IL-9 by immature T lymphocytes, while IL-17 neutralizing antibody and tanshinone IIA significantly inhibited the secretion of IL-9 by immature T lymphocytes and reversed the promoting effect of IL-17 and SSc serum (**Fig. 5C**).

3. Effects of IL-17 and IL-9 on the functional activation of DVSMCs and regulation of tanshinone IIA

3.1 IL-9 and SSc serum promote the expression of IL-17R in DVSMCs, and tanshinone IIA reverses this effect

The DVSMCs of SSc patients were isolated and incubated with IL-9, IL-9 neutralizing antibody, SSc serum, SSc serum and IL-9 neutralizing antibody, tanshinone IIA, IL-9 and tanshinone IIA, and SSc serum and tanshinone IIA for 3 days. The expression of IL-17R was detected by immunofluorescence. The results showed that IL-9 and SSc serum significantly promote the expression of IL-17R, and IL-9 neutralizing antibody and tanshinone IIA reversed the promoting effect of IL-9 and SSc serum (**Fig. 6**).

3.2 IL-17 and SSc serum promote the expression of IL-9R in DVSMCs, and tanshinone IIA reverses this effect

The DVSMCs were incubated with IL-17, IL-17 neutralizing antibody, SSc serum, SSc serum and IL-17 neutralizing antibody, tanshinone IIA, IL-17 and tanshinone IIA, and SSc serum and tanshinone IIA for 3

days. The expression of IL-9R was detected by immunofluorescence. The results showed that IL-17 and SSc serum significantly promote the expression of IL-9R, and IL-17 neutralizing antibody and tanshinone IIA reversed the promoting effect of IL-17 and SSc serum (**Fig. 7**).

3.3 IL-9 and SSc serum promote the functional activation of DVSMCs, and tanshinone IIA reverses this effect

The DVSMCs were incubated with IL-9, IL-9 and IL-9 neutralizing antibodies, IL-9 and tanshinone IIA, SSc serum, SSc serum and IL-9 neutralizing antibodies, and SSc serum and tanshinone IIA for 3 days. Collagen I, collagen III, α -SMA, P-P38, P38, P-ERK, and ERK were detected by WB. The results showed that IL-9 and SSc serum significantly promote the expression of collagen I, collagen III, α -SMA, P-P38, and P-ERK. Moreover, IL-9 neutralizing antibody and tanshinone IIA reversed the effects of IL-9 and SSc serum (**Fig. 8**).

3.4 IL-17 and SSc serum promote the functional activation of DVSMCs, and tanshinone IIA reverse this effect

The DVSMCs were incubated with IL-17, IL-17 and IL-17 neutralizing antibodies, IL-17 and tanshinone IIA, SSc serum, SSc serum and IL-17 neutralizing antibodies, and SSc serum and tanshinone IIA for 3 days. Collagen I, collagen III, α -SMA, P-P38, P38, P-ERK, and ERK were detected by WB. The results showed that IL-17 and SSc serum significantly promote the expression of collagen I, collagen III, α -SMA, P-P38, and P-ERK. IL-17 neutralizing antibody and tanshinone IIA reversed the effects of IL-17 and SSc serum (**Fig. 9**).

3.5 Tanshinone IIA inhibits the synergistic effect of IL-9 and IL-17 on functional activation of DVSMCs

DVSMCs were treated with IL-17, IL-9, IL-17 and IL-9, IL-17 neutralizing antibody and IL-9 neutralizing antibody, IL-17 and IL-9 and tanshinone IIA, SSc serum, SSc serum/IL-17 neutralizing antibody/IL-9 neutralizing antibody, and SSc serum and tanshinone IIA for 3 days. The proteins were collected for WB detection of collagen I, collagen III, α -SMA, P-P38, P38, P-ERK, and ERK. The results showed that IL-17, IL-9, and SSc serum significantly promote the expression of collagen I, collagen III, α -SMA, P-P38, and P-ERK. In addition, IL-9 and IL-17 neutralizing antibodies and tanshinone IIA inhibited the synergistic effect of IL-9 and IL-17 (**Fig. 10**).

Discussion

Th9, a defined subset of T helper cells, has been identified by the potent production of IL-9 [16], which is a protein of 144 amino acids with a secretory signal sequence of 18 amino acids. Interestingly, IL-9 binds to IL-9R on target cells [17]. Although the role of Th9 cell subset has been described recently in many types of inflammatory diseases (namely, atopic diseases, parasitic inflammation, experimental autoimmune encephalomyelitis, and inflammatory bowel diseases) [18-23], the role in the pathogenesis of rheumatic diseases, such as SSc, is yet unknown.

The presence of high IL-9 levels and the strong expression of Th9 in SSc raise the concern of whether Th9 cells might participate in SSc pathogenesis. In this [study](#), the strong expression of IL-9R has been demonstrated recently in the skin tissue of patients with SSc. [Also](#), IL-9 expression was observed in the PBMCs from SSc patients. The majority of IL-9-producing cells in the skin were identified as Th9 cells. Among peripheral blood mononuclear cells, Th9 cells are the major source of IL-9, which is significantly expanded in SSc patients as compared to the controls. The participation of IL-9 and Th9 in the process of inflammation and fibrosis in SSc is yet elucidated.

Our previous research has confirmed that IL-17 and Th17 enhance the proliferation, collagen synthesis and secretion, and migration of SSc patient-derived DVSMCs [via](#) mitogen-activated protein kinase (MAPKs) signaling pathway [9]. In addition, the previous [study](#) also demonstrated that tanshinone IIA (C19H18O3), a fat-soluble pharmacologically active component of the Chinese herb *Sativa miltiorrhiza* that is a well-known traditional Chinese medicine used for the treatment of cardiovascular and connective tissue diseases, exerts an inhibitory effect on the functional activation of SSc patient-derived DVSMCs [10].

The present study focuses on the co-effects of Th17 and Th9 cells on SSc patient-derived DVSMCs. We also studied the regulatory effect of tanshinone IIA on this process. Th17 and Th9 promote each other's differentiation from immature T lymphocytes via characteristic cytokines IL-17 and IL-9. IL-17, IL-9, and SSc serum promoted the expression of collagen I, collagen III, α -SMA, P-P38, and P-ERK, [inducing](#) the functional activation of DVSMCs. Increased collagen synthesis and secretion of DVSMCs indicates the aggravation of angiopathy and fibrosis in SSc. [Nevertheless](#), IL-17 and IL-9 neutralizing antibodies and tanshinone IIA reverse the effects.

Conclusion

The results of this study revealed the effect of T cell interaction on the functional activation of SSc VSMCs. Thus, the correlation between cellular immune abnormality and angiogenesis in the pathogenesis of SSc is detected, which provides a theoretical and experimental basis for SSc to find new therapeutic targets and drugs.

Abbreviations

α -SMA, α -smooth muscle actin; DVSMCs, dermal vascular smooth muscle cells; ELISA, enzyme-linked immunosorbent assay; ERK, extracellular regulated protein kinases; IL-9, interleukin-9; IL-9R, interleukin-9 receptor; IL-17A, interleukin-17A; IL-17R, interleukin-17 receptor; MAPK, mitogen-activated protein kinases; PBMCs, peripheral blood mononuclear cells; PBS, phosphate-buffered saline; SSc, systemic sclerosis; Th9, T helper 17; Th17, T helper 17

Declarations

Ethics approval and consent to participate

This study was performed in accordance with the Declaration of Helsinki and the principles of Good Clinical Practice. Biological samples were obtained under a protocol approved by the Institutional Research Ethics Committee of Huashan Hospital of Fudan University (ID: 2016-081), Shanghai, China. All subjects provided written informed consent before participation in the study.

Consent for publication

All the authors provided consent for the publication of this article.

Availability of data and materials

Data and materials were all available.

Competing interests

We confirm that all the listed authors have participated actively in the study, and have seen and approved the submitted manuscript. The authors do not have any possible conflicts of interest.

Funding

This work was supported by the National Natural Science Foundation of China (81602747).

Authors' contributions

MGL designed and conducted the experiments, performed the statistical analysis, and wrote and revised the manuscript. ML and WWF revised the manuscript. All authors read and approved the final manuscript.

Acknowledgments

We thank all the patients who participated in this study.

References

1. Pillai S: **T and B lymphocytes in fibrosis and systemic sclerosis.***Curr Opin Rheumatol* 2019, **31**:576-581.
2. Shi X, Liu Q, Zhao H, Lu J, Huang Y, Ma Y, Xia J, Liu M, Tu W, Jin L, et al: **Increased expression of GAB1 promotes inflammation and fibrosis in systemic sclerosis.***Exp Dermatol* 2019.
3. Henry TW, Mendoza FA, Jimenez SA: **Role of microRNA in the pathogenesis of systemic sclerosis tissue fibrosis and vasculopathy.***Autoimmun Rev* 2019:102396.
4. Di Benedetto P, Ruscitti P, Liakouli V, Cipriani P, Giacomelli R: **The Vessels Contribute to Fibrosis in Systemic Sclerosis.***Isr Med Assoc J* 2019, **21**:471-474.

- 5.Trojanowska M: **Cellular and molecular aspects of vascular dysfunction in systemic sclerosis.***Nat Rev Rheumatol* 2010, **6**:453-460.
- 6.Jun JB, Kuechle M, Harlan JM, Elkon KB: **Fibroblast and endothelial apoptosis in systemic sclerosis.***Curr Opin Rheumatol* 2003, **15**:756-760.
- 7.Yang X, Yang J, Xing X, Wan L, Li M: **Increased frequency of Th17 cells in systemic sclerosis is related to disease activity and collagen overproduction.***Arthritis Res Ther* 2014, **16**:R4.
- 8.Xing X, Yang J, Yang X, Wei Y, Zhu L, Gao D, Li M: **IL-17A induces endothelial inflammation in systemic sclerosis via the ERK signaling pathway.***Plos One* 2013, **8**:e85032.
- 9.Liu M, Yang J, Xing X, Cui X, Li M: **Interleukin-17A promotes functional activation of systemic sclerosis patient-derived dermal vascular smooth muscle cells by extracellular-regulated protein kinases signalling pathway.***Arthritis Res Ther* 2014, **16**:4223.
- 10.Liu M, Yang J, Li M: **Tanshinone IIA attenuates interleukin-17A-induced systemic sclerosis patient-derived dermal vascular smooth muscle cell activation via inhibition of the extracellular signal-regulated kinase signaling pathway.***Clinics (Sao Paulo)* 2015, **70**:250-256.
- 11.Liu M, Wu W, Sun X, Yang J, Xu J, Fu W, Li M: **New insights into CD4(+) T cell abnormalities in systemic sclerosis.***Cytokine Growth Factor Rev* 2016, **28**:31-36.
- 12.Guggino G, Lo PM, Di Liberto D, Rizzo A, Cipriani P, Ruscitti P, Candore G, Gambino CM, Sireci G, Dieli F, et al: **Interleukin-9 over-expression and T helper 9 polarization in systemic sclerosis patients.***Clin Exp Immunol* 2017, **190**:208-216.
- 13.Ciccica F, Guggino G, Ferrante A, Cipriani P, Giacomelli R, Triolo G: **Interleukin-9 and T helper type 9 cells in rheumatic diseases.***Clin Exp Immunol* 2016, **185**:125-132.
- 14.Nowak EC, Weaver CT, Turner H, Begum-Haque S, Becher B, Schreiner B, Coyle AJ, Kasper LH, Noelle RJ: **IL-9 as a mediator of Th17-driven inflammatory disease.***J Exp Med* 2009, **206**:1653-1660.
- 15.Elyaman W, Bradshaw EM, Uyttenhove C, Dardalhon V, Awasthi A, Imitola J, Bettelli E, Oukka M, van Snick J, Renauld JC, et al: **IL-9 induces differentiation of TH17 cells and enhances function of FoxP3+ natural regulatory T cells.***Proc Natl Acad Sci U S A* 2009, **106**:12885-12890.
- 16.Li J, Chen S, Xiao X, Zhao Y, Ding W, Li XC: **IL-9 and Th9 cells in health and diseases-From tolerance to immunopathology.***Cytokine Growth Factor Rev* 2017, **37**:47-55.
- 17.De Smedt M, Verhasselt B, Kerre T, Vanhecke D, Naessens E, Leclercq G, Renauld JC, Van Snick J, Plum J: **Signals from the IL-9 receptor are critical for the early stages of human intrathymic T cell development.***J Immunol* 2000, **164**:1761-1767.

- 18.Kerzerho J, Maazi H, Speak AO, Szely N, Lombardi V, Khoo B, Geryak S, Lam J, Soroosh P, Van Snick J, Akbari O: **Programmed cell death ligand 2 regulates TH9 differentiation and induction of chronic airway hyperreactivity.***J Allergy Clin Immunol* 2013, **131**:1048-1057, 1051-1057.
- 19.Nalleweg N, Chiriac MT, Podstawa E, Lehmann C, Rau TT, Atreya R, Krauss E, Hundorfean G, Fichtner-Feigl S, Hartmann A, et al: **IL-9 and its receptor are predominantly involved in the pathogenesis of UC.***Gut* 2015, **64**:743-755.
- 20.Weigmann B, Neurath MF: **Th9 cells in inflammatory bowel diseases.***Semin Immunopathol* 2017, **39**:89-95.
- 21.Elyaman W, Khoury SJ: **Th9 cells in the pathogenesis of EAE and multiple sclerosis.***Semin Immunopathol* 2017, **39**:79-87.
- 22.Angkasekwinai P: **Allergic Inflammation and Atopic Disease: Role of Th9 Cells.***Methods Mol Biol* 2017, **1585**:189-199.
- 23.Pinto M, Licona-Limon P: **Th9 Cells and Parasitic Inflammation: Use of Nippostrongylus and Schistosoma Models.***Methods Mol Biol* 2017, **1585**:223-245.

Figures

Figure 1

IL-17R and IL-9R were highly expressed in skin tissues of SSc patients. A. Compared to healthy control, IL-17R was highly expressed in the skin tissue of SSc patients. α -SMA, red fluorescence, 1:200. IL-17R, green fluorescence, 1:200. B. Compared to healthy control, IL-9R was highly expressed in the skin tissue of SSc patients. α -SMA, red fluorescence, 1:200. IL-9R, green fluorescence, 1:200.

Figure 2

High expression of IL-9 and IL-9R in patients with SSc. A. High expression of IL-9 mRNA in PBMCs of SSc patients. B. High expression of IL-9R mRNA in PBMCs of SSc patients. C. High expression of IL-9 in the serum of SSc patients. N means Normal, P means Patient. * vs. N, $P < 0.05$. ** vs. N, $P < 0.01$. *** vs. N, $P < 0.001$.

Figure 3

The proportion of CD4+IL-9+ T cells in PBMCs of SSc patients was significantly higher than that of healthy controls.

Figure 4

IL-9 neutralizing antibody and Tanshinone IIA inhibit the differentiation of immature T lymphocytes into Th17. A and B. The proportion of immature T lymphocytes differentiated into Th17 in each group was detected using flow cytometry. C. The content of IL-17 secreted by immature T lymphocytes in each group was detected by ELISA. IL-9 concentration 20 ng/mL, anti-IL-9 concentration 5 µg/mL, Tanshinone IIA

concentration 50 μ M. * vs. control group, $P<0.05$, *** vs. control group, $P<0.001$, ## vs. IL-9 group, $P<0.01$, ### vs. IL-9 group, $P<0.001$.

Figure 5

IL-17 neutralizing antibody and Tanshinone IIA inhibit the differentiation of immature T lymphocytes into Th9. A and B. The proportion of immature T lymphocytes differentiated into Th9 in each group was detected using flow cytometry. C. The content of IL-9 secreted by immature T lymphocytes in each group

was detected by ELISA. IL-17 concentration 100 ng/mL, anti-IL-17 concentration 8 µg/mL, Tanshinone IIA concentration 50 µM. * vs. control group, P<0.05, *** vs. control group, P<0.001, ### vs. IL-9 group, P<0.001.

Figure 6

IL-9 neutralizing antibody and Tanshinone IIA inhibit the expression of IL-17R in DVSMCs. α -SMA, red fluorescence; IL-17R, green fluorescence.

Figure 7

IL-17 neutralizing antibody and Tanshinone IIA inhibit the expression of IL-9R in DVSMCs. α -SMA, red fluorescence; IL-9R, green fluorescence.

Figure 8

Expression of various fibrosis-related and signaling pathway-related proteins in functionally-activated DVSMCs were detected by Western blot. A. Immunoreactive bands of Western blot of various proteins. IL-9 promotes the expression of various proteins in DVSMCs, which is inhibited by Tanshinone IIA. B–H. Western blot data of collagen I, collagen III, α -SMA, P-P38, P-ERK, and ERK are represented as statistical graphs.

Figure 9

Expression of various fibrosis-related and signaling pathway-related proteins in functionally-activated DVSMCs were detected by Western blot. **A** Immunoreactive bands of Western blot of various proteins. IL-17 promotes the expression of various proteins in DVSMCs, which is inhibited by Tanshinone IIA. **B–H**. Western blot results of collagen I, collagen III, α -SMA, P-P38, P-ERK, and ERK are expressed in the form of statistical graphs.

Figure 10

Expression of various fibrosis-related and signaling pathway-related proteins in functional activated DVSMCs were detected by Western blot. A. Immunoreactive bands of Western blot of various proteins. IL-9 and IL-17 play a synergistic role in promoting the expression of various proteins in DVSMCs, which is inhibited by Tanshinone IIA. B–H. Western blot data of collagen I, collagen III, α-SMA, P-P38, P-ERK, and ERK are represented as graphs.